documents: FDA-2025-N-4682-0001

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2025-N-4682-0001 FDA FDA-2025-N-4682 Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Notice Notice of Approval 2025-12-19T05:00:00Z 2025 12 2025-12-19T05:00:00Z   2025-12-19T20:02:51Z 2025-23410 0 0 09000064b90f51e4

Links from other tables